All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and...
IN8bio, Inc. (NASDAQ:INAB Free Report) Equities research analysts at HC Wainwright increased their FY2023 earnings per share estimates for shares of IN8bio in a research note issued...
IN8bio (NASDAQ:INAB Get Free Report)s stock had its buy rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on...
Company will present late-breaker poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs...
Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number...
Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune...
This data represents a step forward in developing next-generation 'off-the-shelf' iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential...
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and...
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...